Medihauxe Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 1.50 Cr
- Company Age 10 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 31.00 Cr
- Revenue Growth -12.95%
- Profit Growth 107.77%
- Ebitda 14.67%
- Net Worth 17.92%
- Total Assets 0.56%
About Medihauxe Pharma
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24233TG2014PTC094068
- Company No.
094068
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 May 2014
- Date of AGM
08 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
What products or services does Medihauxe Pharma Private Limited offer?
Medihauxe Pharma Private Limited offers a wide range of products and services, including Cardiovascular Drugs & Medication, Immunosuppressive Drugs, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Anti Cancer Injection, Veenat Tablet, Geftinat Tablet, Anaemia Medicine, Epofit Injection, Anastrozole Tablets.
Who are the key members and board of directors at Medihauxe Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Girishbhat Padukudru  | Managing Director | 16-May-2014 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Arvind Venkat | Nominee Director | 11-Sep-2014 | Current |
| Manohar Padakuduru | Whole-Time Director | 16-May-2014 | Current |
| Yashwant Singh | Director | 07-Sep-2020 | Current |
Financial Performance of Medihauxe Pharma.
Medihauxe Pharma Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 12.95% decrease. The company also saw a substantial improvement in profitability, with a 107.77% increase in profit. The company's net worth Soared by an impressive increase of 17.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medihauxe Pharma?
In 2023, Medihauxe Pharma had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Keimed Private LimitedArvind Venkat is a mutual person
Neelkanth Drugs Private LimitedArvind Venkat and Yashwant Singh are mutual person
Auspharma Private LimitedArvind Venkat is a mutual person
- Prime Time Logistics Technologies Private Limited
Arvind Venkat is a mutual person
- Medihauxe Pharmaceuticals Private Limited
Girishbhat Padukudru and Manohar Padakuduru are mutual person
Charges (Loans)
₹0
₹31.00 Cr
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 31.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Jul 2016 | Hdfc Bank Limited | ₹1.00 Cr | Satisfied |
| 20 Aug 2014 | Hdfc Bank Limited | ₹30.00 Cr | Satisfied |
How Many Employees Work at Medihauxe Pharma?
Medihauxe Pharma has a workforce of 67 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medihauxe Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medihauxe Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
